SMPD1 and cardiomyopathy: To explore the therapeutic potential of ASMase in HFD-induced cardiomyopathy and exclude the systemic influence of drug, we generated ASMaseMyh6KO mice by CRISPR/Cas9 genome-editing technology confirmed ASMase depletion in vivo.